The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy

Brahma, Bayu; Putri, Rizky Ifandriani; Sari, Lenny; Karsono, Ramadhan; Purwanto, Denni Joko; Gautama, Walta; Andinata, Bob; Haryono, Samuel J

doi:10.3791/57201

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies reported IFR up to 34% in retro‐areolar blue dye injection [1, 21, 22]. The significant reduction in failure rate ( P value of < 0.001) in group A indicates that using lateral blue dye injection alone can produce the comparable results to the use of either radioactive colloid alone or in combination with blue dye (reported failure rates are between 0 and 13% [5, 22–25] and 2 to 19%, respectively [12, 26–29]). In addition, patent blue is a cheaper and more available alternative in developing countries who lack appropriate funds and resources.…”

Section: Discussionmentioning

confidence: 84%

Assessment of Intraparenchymal Injection of 1% Patent Blue Dye in the Upper Outer Quadrant of the Breast to Identify Sentinel Lymph Node in Early Retro‐Areolar Breast Cancer in Women: A Tertiary Centre Experience in Egypt

Fouad

Ibraheim

2022

World j. surg.

View full text Add to dashboard Cite

Background Sentinel lymph node biopsy is the gold standard for axillary assessment of patients with clinically node negative breast cancer. The current internationally accepted methods comprise of the usage of either a radioactive tracer, vital stains or the combination of both. However, in developing countries radioactive tracer is not widely used due to its high cost and limited availability. In addition, the classic retro-areolar blue dye injection has a high failure rate.Objective Our study aimed to assess the efficacy of patent blue dye injection in the upper outer quadrant of the breast after validation by concurrent usage of radioactive nanocolloid, in comparison with the classic retro-areolar injection in identifying the sentinel node. Methods A randomized control study involving 279 patients randomly divided into two groups. In group A lateral injection of 1% patent blue dye (validated by radioactive nanocolloid) was used, while subdermal patent blue dye injection in the retro-areolar space was performed in group B. ResultsThe new technique showed the promising results with lower failure rate (3.4%) in comparison with the classic retro-areolar patent blue injection (13.7%). Conclusions The lateral injection technique can be result in comparable results to the combination technique with the added benefit of being widely available and a cheaper option especially in developing countries.

show abstract

Section: Discussionmentioning

confidence: 84%

Assessment of Intraparenchymal Injection of 1% Patent Blue Dye in the Upper Outer Quadrant of the Breast to Identify Sentinel Lymph Node in Early Retro‐Areolar Breast Cancer in Women: A Tertiary Centre Experience in Egypt

Fouad

Ibraheim

2022

World j. surg.

View full text Add to dashboard Cite

show abstract

Azul de metileno, opción para la marcación de cáncer colorrectal pre procedimiento mínimamente invasivo. Reporte de caso

Domínguez Alvarado,

Quintero Arias,

Bermúdez Mantilla

et al. 2023

Rev. Médica Risaralda

View full text Add to dashboard Cite

El cáncer colorrectal es una patología común que causa aproximadamente 861,000 muertes al año. Se presenta el caso de un paciente masculino de 50 años, con hipertensión arterial y Diabetes mellitus tipo II, con diagnóstico de neoplasia en colon descendente, al cual se le realizó procedimiento mínimamente invasivo, posterior a marcación tumoral con azul de metileno por medio de endoscopia de vías digestiva bajas. Postoperatorio adecuado, sin complicaciones. El tratamiento de elección para el cáncer colorrectal sin metástasis es la exeresis oncológica. Actualmente, el manejo quirúrgico recomendado es por medio de procedimiento mínimamente invasivo, sin embargo, es un desafío puesto que en algunos casos la identificación de la lesión es difícil y adicionalmente requiere una curva de aprendizaje pronunciada. Por lo anterior, utilizamos el azul de metileno para la marcación del tumor previo procedimiento, con excelentes resultados, sin complicaciones. La marcación tumoral con azul de metileno previa al procedimiento mínimamente invasivo es seguro, útil, económico y de bajo riesgo.

show abstract

Techniques for sentinel node biopsy in breast cancer

Bove¹,

Fragomeni

Romito³

et al. 2021

Minerva Surg

View full text Add to dashboard Cite

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy

Cited by 3 publications

References 0 publications

Assessment of Intraparenchymal Injection of 1% Patent Blue Dye in the Upper Outer Quadrant of the Breast to Identify Sentinel Lymph Node in Early Retro‐Areolar Breast Cancer in Women: A Tertiary Centre Experience in Egypt

Assessment of Intraparenchymal Injection of 1% Patent Blue Dye in the Upper Outer Quadrant of the Breast to Identify Sentinel Lymph Node in Early Retro‐Areolar Breast Cancer in Women: A Tertiary Centre Experience in Egypt

Azul de metileno, opción para la marcación de cáncer colorrectal pre procedimiento mínimamente invasivo. Reporte de caso

Techniques for sentinel node biopsy in breast cancer

Contact Info

Product

Resources

About